An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia
Open Access
- 11 April 2026
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Abstract
Background: The molecular landscape of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has been extensively characterized through single-modality studies. However, the interplay between molecular modalities and their collective influence on treatment response and outcomes remains poorly understood. Methods: We integrated genomic, epigenomic, transcriptomic, and ex vivo drug response data from 1231 patients diagnosed with BCP-ALL. Using Multi-Omics Factor Analysis, we identified signatures explaining key aspects of the integrative molecular landscape, referred to as cross-modal elements (CMEs). The CME-derived signatures were introduced into pathway and intermodal network analyses, while their impact on patient outcomes was assessed through survival modeling. Results: Pathway and network analyses annotate the resulting integrative CMEs, linking them to key biological processes, including disease development, cellular regulatory processes, metabolic pathways, and drug response. By leveraging correlations between DNA methylation and ex vivo response to doxorubicin, we stratify patients with hyperdiploidy into subgroups that differ in relapse-free survival. These signatures are independent of clinical variables. Survival models incorporating CME-selected ex-vivo drug responses combined with clinical data improve risk prediction compared to clinical models alone (FDR < 0.05), demonstrating the potential of integrative multiomics in refining risk stratification. Conclusions: Our study highlights the importance of multimodal data integration in BCP-ALL to provide biological insights with potential relevance for precision medicine.Keywords
This publication has 77 references indexed in Scilit:
- Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patientsHemaSphere, 2025
- A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocoleJHaem, 2024
- Integration of multi-omics analysis reveals metabolic alterations of B lymphocytes in systemic lupus erythematosusClinical Immunology, 2024
- International Consensus Classification of acute lymphoblastic leukemia/lymphomaVirchows Archiv, 2022
- Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaCancer Cell, 2022
- Molecular markers in ALL: Clinical implicationsBest Practice & Research Clinical Haematology, 2020
- Identification of an AP1-ZFP36 Regulatory Network Associated with Breast Cancer PrognosisJournal of Mammary Gland Biology and Neoplasia, 2020
- The AP-1 transcriptional complex: Local switch or remote command?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- Targeting Metabolism for Cancer TherapyCell Chemical Biology, 2017
- The Mutational Landscape in Pediatric Acute Lymphoblastic Leukemia Deciphered by Whole Genome SequencingHuman Mutation, 2014